Overview

Trial of Pemetrexed for Patients With Pancreatic Cancer Which Cannot be Treated With Surgery or is Metastatic

Status:
Completed
Trial end date:
2005-04-01
Target enrollment:
Participant gender:
Summary
This study with pemetrexed is for patients with metastatic or unresectable pancreatic cancer who progressed after first line chemotherapy with gemcitabine.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Pemetrexed